Worldwide Prevalence and Clinical Characteristics of RAS Mutations in Head and Neck Cancer: A Systematic Review and Meta-Analysis.

KRAS (OR = 2.41; 95% CI, 0.85-6.86) and NRAS (OR = 1.52; 95% CI, 0.68-3.41) mutations were both associated with an OR>1, but the association did not reach statistical significance ( Figure S4 in the Supplementary Material ). 3.8 Association Between RAS Mutations and HPV Status Of the 38 cohort studies that reported the HPV status of HNC patients, only 25 provided specific patient data, and of these, 17 included both HPV-negative and HPV-positive patients, thus allowing an OR analysis.

also in 111,027 other papers